BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bolton Medical Receives FDA Approval for the Relay® Thoracic Stent-Graft, a Minimally-Invasive Treatment for Thoracic Aortic Aneurysms and Penetrating Ulcers


9/27/2012 6:36:37 AM

SUNRISE, FL--(Marketwire - September 26, 2012) -

Bolton Medical announced today that they have received approval from the U.S. Food and Drug Administration for the Relay Thoracic Stent-Graft with Plus Delivery System.

Specifically designed for the thoracic aorta, the Relay device is offered in a wide range of sizes to help to expand the use of this minimally-invasive treatment for thoracic aortic aneurysms and penetrating atherosclerotic ulcers.

Bolton Medical stent-grafts have been widely used in Europe and other international markets since 2005 and, to date, more than 7,000 Relay and Relay NBS Thoracic Stent-Grafts have been implanted worldwide. The U.S. pivotal study included 120 endovascular patients at 30 hospitals across the country.

National Principal Investigator, Dr. Mark Farber, Director, UNC Aortic Center; Vascular Surgery Program Director; Associate Professor of Surgery and Radiology stated, "The Relay Thoracic Stent-Graft allows for precision and conformability, especially in patients with more challenging anatomies. As a physician, I find that the Relay device makes it easier for me to offer this life-saving treatment to a broader population of patients suffering from thoracic aortic aneurysm."

The Relay system offers the following features:

  • Distinct performance zones provide varying levels of radial support and apposition.
  • Four-step dual sheath delivery system.
  • Wide range of sizes to meet patient needs: lengths of 100mm-250mm, diameters of 22-46mm, straight and tapered.

"With worldwide experience of the Relay family of devices, we are pleased that the FDA has now approved the use of this device in the United States. We believe that U.S. physicians will benefit tremendously from access to the latest medical technology of the Relay Thoracic Stent-Graft with Plus Delivery System," said Oscar Rospigliosi, CEO, Bolton Medical, Inc.

COMPANY

Bolton Medical currently manufactures Relay and Relay NBS Thoracic Stent-Grafts. They are used worldwide for the treatment of main thoracic aortic pathologies. To date, approximately 7,000 Relay and Relay NBS Thoracic Stent-Grafts have been implanted worldwide. Bolton Medical is a private company, with European operations based in Barcelona, Spain, and U.S. operations in Sunrise, Florida. Bolton Medical is a wholly-owned subsidiary of the Werfen Life Group, a diverse manufacturer and supplier of products for the medical industry.

For more information on Relay Thoracic Stent-Graft with Plus Delivery System, please visit www.boltonmedical.com.


Candace DeLeonardis
954-636-9785



Read at BioSpace.com

   
Aneurysm

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES